Glybenclamide (NLRP3 Inhibitor)

Glybenclamide, also known as glyburide, is an ATP-sensitive potassion channel inhibitor. It has been shown to inhibit various biological processes including PAMP and DAMP-induced activation of the NRLP3 inflammasome as well as the activation of the inflammasome by crystalline substances. Although the mechanism remains to be fully elucidated, evidence suggests that this inhibitor acts downstream of the P2X7 receptor but upsteam of NLRP3. It also blocks maturation of caspase-1 and pro-IL-1b; this occurs through inhibition of K+ efflux. Glybenclamide/Glyburide has a number of additional functions besides blocking. For example, in cultured cells it has been shown to enhance insulin action and stimulates the synthesis of glucose transporters. In this regard, it has gained recognition for studying the mechanisms of Type II diabetes. Researchers are encouraged to consult the published literature regarding additional information about how glybenclamide perturbs biological processes.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Inhibitors are guaranteed for 1 year from date of receipt.

We have publications tested in 2 confirmed species: Human, Mouse.

We have publications tested in 2 applications: In-Cell Western (ICW), N/A.

Showing Publications 1 - 7 of 7.

Publications using NBP2-30141	Applications	Species
Phulphagar K, Kuhn LI, Ebner S et al. Proteomics reveals distinct mechanisms regulating the release of cytokines and alarmins during pyroptosis Cell reports 2021-03-09 [PMID: 33691121]
Iida T, Daisuke Hirayama , Minami N et al. Downregulation of RalGTPase-activating protein promotes colitis-associated cancer via NLRP3 inflammasome activation Cell Mol Gastroenterol Hepatol 2019-10-14 [PMID: 31622786] (N/A, Mouse)	N/A	Mouse
Assetta B, Morris-Love J, Gee GV et al. Dysregulation of Gap Junction Function and Cytokine Production in Response to Non-Genotoxic Polycyclic Aromatic Hydrocarbons in an In Vitro Lung Cell Model Cancers (Basel) 2019-04-23 [PMID: 31018556] (In-Cell Western (ICW), Mouse)	In-Cell Western (ICW)	Mouse
Qin L, Fengyong Z, Jiamin Z et al. NLRP3 Inflammasome Activation Regulates Aged RBC Clearance. Inflammation 2018-04-21 [PMID: 29680907] (In-Cell Western (ICW), Human)	In-Cell Western (ICW)	Human
Hsieh CW, Chen YM, Lin CC et al. Elevated Expression of the NLRP3 Inflammasome and Its Correlation with Disease Activity in Adult-onset Still Disease. J. Rheumatol. 2017-05-15 [PMID: 28507179] (In-Cell Western (ICW), Human)	In-Cell Western (ICW)	Human
Zhang F, Wang L, Wang JJ et al. The caspase-1 inhibitor AC-YVAD-CMK attenuates acute gastric injury in mice: involvement of silencing NLRP3 inflammasome activities. Sci Rep. 2016-04-07 [PMID: 27053298]
Cho JS, Guo Y, Ramos RI et al. Neutrophil-derived IL-1B is sufficient for abscess formation in immunity against Staphylococcus aureus in mice. PLoS Pathog. 2012-01-01 [PMID: 23209417] (Mouse) Details: Inhibition of S. aureus (Fig 6C) and MRSA (Fig 6D) activation in mouse neutrophils isolated from mouse bone marrow. The glibenclamide inhibitor was used at 100 micromolar. Readout assay: IL-1B production. Glibenclamide inhibited IL-1B production by about		Mouse

Array NBP2-30141

• Glybenclamide Inhibitor